66th ASH Annual Meeting: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Understanding and Improving TCE and CAR-T Cell Therapies for Plasma Cell Disorders

Symposia: Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational Oral and Poster Abstracts
Oral

Research, Fundamental Science, Combination therapy, Translational Research, Bispecific Antibody Therapy, Plasma Cell Disorders, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Immune mechanism, Treatment Considerations, Biological therapies, Immunology, Lymphoid Malignancies, Biological Processes

Pacific Ballroom Salons 18-19 (Marriott Marquis San Diego Marina)

Moderators:

Suzanne Lentzsch, MD, PhD, Columbia University Medical Center and Michele Cea, IRCCS Ospedale Policlinico San Martino

Disclosures:

Lentzsch: BMS: Consultancy; Janssen: Consultancy; Regeneron: Honoraria; Pfizer: Consultancy; Sanofi: Consultancy, Research Funding; Caelum Bioscience: Patents & Royalties: CAEL-101; GSK: Honoraria; Alexion: Consultancy.

4:00 PM

355

Direct Visualisation of BCMA Bispecific Antibody and the Myeloma Immune Microenvironment

Jeremy Er^1,2, Rimes Joel, BSc, PhD²^*, Light Amanda, BSc²^*, Mark R Dowling, MBBS, PhD³, Simon J Harrison, MBBS, PhD^4,5 and Edwin Hawkins, BSc, PhD²^*

¹Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Melbourne, AUS
²Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia
³Centre of Excellence for Cellular Immunotherapy and Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia
⁴Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia
⁵Clinical Haematology and Centre of Excellence for Cellular Immunotherapy, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia

4:15 PM

356

Celmod-Dexamethasone Combination Overcomes Primary Resistance to T Cell Engagers Caused By High Tumor Burden in a Human CRBN⁺ Preclinical Model of Multiple Myeloma

Erin W Meermeier, PhD^1,2^*, Meaghen Sharik, BS¹^*, Megan Du, MS¹^*, Caleb K Stein, PhD¹^*, Yuan Xiao Zhu, PhD¹^*, Chang-Xin Shi, PhD¹^*, Yuliza Shotts, MS¹^*, Leif Bergsagel, MD¹ and Marta Chesi, PhD¹

¹Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Scottsdale, AZ
²Department of Immunology, Mayo Clinic Arizona, Scottsdale, AZ

4:30 PM

357

Combined PD-1 and Tim-3 Blockade Improves the in Vitro Anti-Myeloma Activity of T Cells of Patients on Talquetamab

Tarek H. Mouhieddine, MD¹, Junia Vieira, MD, PhD²^*, Adolfo Aleman, Jr.²^*, Leah Grossman³^*, David Melnekoff, PhD²^*, Bhaskar Upadhyaya, PhD¹^*, Samantha St. Clair⁴^*, Monica Garcia-Barros⁴^*, Meghana Ram, BSc⁵^*, Santiago Thibaud, MD⁶^*, Adriana Rossi, MD, MSc², Shambavi Richard, MD², Cesar Rodriguez, MD⁶^*, Joshua Richter, MD⁵, Hearn Jay Cho, MD, PhD⁷, Larysa Sanchez, MD⁸^*, Sundar Jagannath, MD², Ajai Chari, MD⁹, Rachel Brody, MD, PhD⁴^*, Christian Salib, MD¹⁰^*, Alessandro Lagana, PhD¹ and Samir Parekh, MD²

¹Department of Medicine, Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York
²Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
³Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York City, NY
⁴Pathology, Icahn School of Medicine at Mount Sinai, New York, NY
⁵Icahn School of Medicine at Mount Sinai, New York, NY
⁶Department of Medicine, Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
⁷Department of Medicine, Hematology and Medical Oncology, Tisch Cancer Institute, Tisch Cancer Institute, New York, NY
⁸Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY
⁹University of California, San Francisco, San Francisco, CA
¹⁰Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY

4:45 PM

358

Combination with Cytotoxic Therapy and Checkpoint Blockade Overcomes Primary Resistance to BCMA Bispecific Antibody Therapy and Leads to Durable Remission of Vk*MYC Multiple Myeloma

Erin W Meermeier, PhD^1,2^*, Caleb K Stein, PhD²^*, Meaghen Sharik, BS²^*, Megan Du, MS²^*, Yuan Xiao Zhu, PhD²^*, Chang-Xin Shi, PhD²^*, Yuliza Shotts, MS²^*, Maria Josic, PhD³^*, Keith Abayasiriwardana, PhD³^*, Natalie Bezman, PhD³^*, Timothy Fisher, BS³^*, Kristin Bompiani-Myers, PhD³^*, Leif Bergsagel, MD² and Marta Chesi, PhD²

¹Department of Immunology, Mayo Clinic, Scottsdale, AZ
²Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Scottsdale, AZ
³Pfizer Inc., San Diego, CA

5:00 PM

359

Enhanced Antitumoral Efficacy of ARI0002h CAR-T with CD28-TMD in Normal and Low BCMA Expressing Myeloma Cells

Luis Gerardo Rodríguez-Lobato¹^*, Oriol Cardus, MSc²^*, Joan Mañé Pujol, MSc²^*, Anthony Battram, PhD²^*, David F. Moreno, MD, PhD³^*, Lorena Perez-Amill, PhD⁴^*, Beatriz Martín-Antonio, PhD⁵^*, Aina Oliver-Caldés, MD, PhD⁶^*, Anna De Daniel, MD⁷^*, Natalia Tovar³^*, M Teresa Cibeira López, MD, PhD⁸^*, Laura Rosinol Dachs, MD, PhD⁹^*, Manel Juan, MD, PhD¹⁰^*, Alvaro Urbano-Ispizua, MD, PhD¹¹ and Carlos Fernández de Larrea, MD³

¹Department of Hematology, Hospital Clínic de Barcelona, Barcelona, Spain., Barcelona, Spain
²Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, ESP
³Hospital Clínic de Barcelona, Barcelona, Spain
⁴Hospital Clínic de Barcelona. IDIBAPS. University of Barcelona, Barcelona, Spain., Barcelona, Spain
⁵Centro de Terapias Avanzadas del Instituto de Salud Carlos III, Madrid, Spain
⁶Hospital Universitari Son Espases, IdISBa, Palma de Mallorca, ESP
⁷Hospital Clínic of Barcelona, Barcelona, ESP
⁸Hospital Clinic of Barcelona, University of Barcelona, IDIBAPS, Barcelona, Spain
⁹Hospital Clinic de Barcelona, IDIBAPS, Barcelona, Spain
¹⁰Department of Immunology. Hospital Clinic de Barcelona. IDIBAPS. Universidad de Barcelona., Barcelona, Spain
¹¹Hematology Department, Hospital Clínic de Barcelona, Barcelona, Spain., Barcelona, Spain

5:15 PM

360

Development of Anti-Amyloid 11-1F4- CAR Phagocytes for Treatment of AL Amyloidosis

Jing Fu, PhD¹, Huihui Ma, PhD, MD²^*, Shirong Li, PhD¹, Michael Sang Hughes, MD³, Gavreel Kalantarov, PhD¹^*, Guifen Liu, MS¹^*, Markus Mapara, MD, PhD²^* and Suzanne Lentzsch, MD, PhD⁴

¹Department of Medicine, Columbia University Irving Medical Center, New York, NY
²Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, NY
³Columbia University Irving Medical Center, New York, NY
⁴Columbia University Herbert Irving Comprehensive Cancer Center, New York, NY

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

651.O1.6 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Understanding and Improving TCE and CAR-T Cell Therapies for Plasma Cell Disorders